Literature DB >> 9676054

Increased risk of malignancy in patients with systemic lupus erythematosus.

R Ramsey-Goldman1, S A Mattai, E Schilling, Y L Chiu, C J Alo, H L Howe, S Manzi.   

Abstract

BACKGROUND: Systemic lupus erythematosus is a chronic, multisystem, autoimmune disorder that primarily affects women. Morbidity and mortality have improved for lupus patients during the last 15 years. An increased risk of malignancy in patients with lupus has been shown in some, but not all studies. The purpose of this study was to ascertain cancer risk in lupus patients by linking two disease registries.
METHODS: Participants in the Chicago Lupus Cohort included 616 women with lupus who were residents of Cook County, Illinois. They were seen during 1985-1995 at 4 University, inner city, and suburban inpatient and outpatient clinics in Chicago. Malignancies occurring in these subjects during the study interval, 1985-1995, were identified from the Illinois State Cancer Registry by matching name, birthdate, and social security number. Standardized incidence ratios (SIRs) were estimated for all malignancies in this cohort of lupus patients using age, gender, and all race or race-stratified specific cancer incidence data from Cook County, Illinois.
RESULTS: The registry linkage study with the Illinois State Cancer Registry documented that 30 women with lupus had a malignancy. The expected number of malignancies for women in the lupus cohort was 15.0. There were 8 cases of breast cancer and 4 each of lung and cervical cancer. In the remaining 14 women, 12 different types of cancers were noted. The SIR and 95% confidence interval (CI) for malignancy for all women with lupus in the study were 2.0 (1.4, 2.9) and lung cancer was the only individual cancer increased in all women--SIR and 95% CI were 3.1 (1.3, 7.9). In the analysis stratified by race, the risk of malignancy (SIR and 95% CI) was increased in Caucasian women, 2.3 (1.4, 3.9). Breast cancer was the only individual cancer increased in Caucasian women with lupus with an SIR and 95% CI of 2.9 (1.4, 6.4).
CONCLUSIONS: Lupus patients have an increased risk of malignancy. Breast, lung, and gynecological malignancies were the most common malignancies observed in the cohort and breast cancer was significantly increased in Caucasian women.

Entities:  

Mesh:

Year:  1998        PMID: 9676054

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  28 in total

Review 1.  Safety of biologic therapy in rheumatoid arthritis.

Authors:  Robert S Woodrick; Eric M Ruderman
Journal:  Nat Rev Rheumatol       Date:  2011-10-11       Impact factor: 20.543

Review 2.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

Review 3.  Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  Male systemic lupus erythematosus, an overlooked diagnosis.

Authors:  Maria do Socorro Teixeira Moreira Almeida; Josué da Costa Arcoverde; Mário Nicolau Barros Jacobino; Antônio Rodrigues Coimbra Neto
Journal:  Clin Pract       Date:  2011-11-08

Review 5.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

6.  p185, an immunodominant epitope, is an autoantigen mimotope.

Authors:  Sanjeev Kumar; John A Hinks; Joseph Maman; Chelliah T Ravirajan; Laurence H Pearl; David A Isenberg
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 7.  Prostate cancer in systemic lupus erythematosus.

Authors:  S Bernatsky; R Ramsey-Goldman; C Gordon; A E Clarke
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

Review 8.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

Review 9.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

10.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.